Expansion of T memory stem cells with superior anti-tumor immunity by Urolithin A-induced mitophagy.

T memory stem cells (T) display increased self-renewal and prolonged survival capabilities, thus preventing T cell exhaustion and promoting effective anti-tumor T cell responses. T cells can be expanded by Urolithin A (UA), which is produced by the commensal gut microbiome from foods rich in ellagitannins and is known to improve mitochondrial health. Oral UA administration to tumor-bearing mice conferred strong anti-tumor CD8 T cell immunity, whereas ex vivo UA pre-treated T cells displayed improved anti-tumor function upon adoptive cell transfer.

Correction: CD95 maintains stem cell-like and non-classical EMT programs in primary human glioblastoma cells.

An amendment to this paper has been published and can be accessed via a link at the top of the paper.

Species- and developmental stage-specific effects of allelopathy and competition of invasive Impatiens glandulifera on co-occurring plants.

Background: Impacts of invasive species on native communities are often difficult to assess, because they depend on a range of factors, such as species identity and traits. Such context-dependencies are poorly understood yet, but knowledge is required to predict the impact of invasions.

Materials And Methods: We assessed species- and developmental stage-specificity of competitive and allelopathic effects of the invasive plant Impatiens glandulifera on different developmental stages of four native plant species.

CD95 maintains stem cell-like and non-classical EMT programs in primary human glioblastoma cells.

Glioblastoma (GBM) is one of the most aggressive types of cancer with limited therapeutic options and unfavorable prognosis. Stemness and non-classical epithelial-to-mesenchymal transition (ncEMT) features underlie the switch from normal to neoplastic states as well as resistance of tumor clones to current therapies. Therefore, identification of ligand/receptor systems maintaining this privileged state is needed to devise efficient cancer therapies.